Cyclerion Therapeutics Inc
CYCN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.28M
Close$
$0.58
97.5% downside
Current Fair Value
97.5% downsideOvervalued by 97.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.28 Million |
|---|---|
| Enterprise Value | $12.89 Million |
| Earnings per Share | $-7.63 |
| Beta | 1.75 |
| Outstanding Shares | 607,286 |
Return
| Return on Equity | -131.85% |
|---|---|
| Return on Assets | -96.78% |
| Return on Invested Capital | -133.24% |
Valuation & Multiples
| P/E Ratio | -2.6 |
|---|---|
| PEG | -0.59 |
| Price to Sales | 7.84 |
| Price to Book Ratio | 2.94 |
| Enterprise Value to Revenue | 6.79 |
| Enterprise Value to EBIT | -1.9 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-7.10
Consensus analyst estimateRevenue Estimate
$1.50 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-50.40
Consensus analyst estimateRevenue Estimate
$550,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 543.14%▲ 516.19% |
|---|---|
| Total Invested | $11.18M▲ 4389.86% |
| Investors Holding | 21▲ 4.00% |
About Cyclerion Therapeutics Inc
1 employees
CEO: Jonathan Violin
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...